Page 10 - Trials Network News Today

The 4-decades long effort to create an AIDS vaccine suffered a blow with news that a vaccine in a late stage trial was discontinued because results showed it to be ineffective. What are the obstacles?

The end of the Mosaico HIV vaccine trial must lead to a continued drive to innovate as well as an urgency to ensure that proven HIV prevention and treatment options reach all who need them, says UNAIDS. Rapid progress against the HIV pandemic is possible if existing prevention and treatment options are made available through the sharing of technologies, expanding provision,

Big Pharma company Johnson & Johnson (J&J) has announced that it has discontinued the creation of an HIV vaccine after a large clinical trial found that the experimental treatment was not [...]

Mosaico trial investigator Dr Stephaun Wallace explains why developing an effective HIV vaccine remains challenging.

BioPharma

By Leroy Leo

The trial was halted after a scheduled data review by the data and safety monitoring committee concluded that the HIV vaccine wasn't working.

Community engagement is "an ongoing constant effort to find the best ways to reach people and thats never a one-off answer. Theres a different answer for every person so its really like a constant sort of space to innovate ways of fostering connections." - in-depth interview participant

Dr. Larry Corey, principal investigator at the HIV Vaccine Trials Network, reflects on the progress made in HIV vaccine trials over the years and how mRNA technology is helping acc

To commemorate World AIDS Day, News Medical spoke to Dr. Larry Corey, an internationally renowned expert in virology, immunology, and vaccine development, and the former president and director of Fred Hutch, about his work within the field of HIV/AIDS research and vaccine development.